Proteomics and biomarkers for detection of endometrial carcinoma

Česká verzia

Authors: M. Kacerovský; J. Tošner
Authors place of work: Porodnická a gynekologická klinika FN Hradec Králové, přednosta doc. MUDr. J. Tošner, CSc. ; Lékařská fakulta Hradec Králové, Univerzita Karlova, Praha
Published in the journal: Ceska Gynekol 2009; 74(4): 274-278
Category: Original Article

Summary

Objective:
The purpose of this study was to focuse on recent developments on the evolving field of biomarker discovery and validation techniques using proteomics platforms for endometrial carcinoma.

Design:
Review.

Setting:
Department of Obstetrics and Gynecology Medical Faculty Charles University Hradec Kralove.

Methods:
The last decade has seen major changes in the technologies used to identify markers for diagnosing endometrial carcinoma. Currently the major developments were made in proteomics area. This new technology hold significant promise in identifying more robust markers for endometrial carcinoma.

Conclusion:
The present review summarizes the results of clinical and experimental research on biomarkers of endometrial carcinoma.

Key words:
proteomics, endometrial carcinoma, biomarker.

Zdroje

1. Bouchard, D., Morriset, D., Bourbonnais, Y., Tremblay, GM. Comprehensive analysis of HE4 expression in normal and malignit human tussues. Mod Pathol, 2006, 63, p. 847-853.

2. Campa, MJ., Wang, MZ., Howard, B., et al. Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin A as potential molecular targets in nonsmall cell lung cancer. Cancer Res, 2003, 63, p.1652-1656.

3. Condeelis, J., Pollard, JW. Macrophages: obligate partners for tumor cell migration, invasion and metastasis. Cell, 2006, 124, p. 263-266.

4. Das, R., Hammamieh, R, Neil, R., Melhem, M. Expression pattern of fatty acid binding proteins in human and carcinoma prostate cells and tissues. Clin Cancer Res, 2001, 7, p. 1706-1715.

5. de Bont, JM., den Boer, ML., Kros, JM., et al. Identification of novel biomarkers in pediatric primitive neuroectodermal tumors nad ependymomas by proteome wide analysis. J Neuropathol Exp Neurol, 2007, 66, p. 505-516.

6. DeSouza, L., Diehl, G., Rodriques, MJ., et al. Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatografy and tandem mass spektrometry. J Proteome Res, 2005, 4, p. 377-386.

7. DeSouza, LV., Grigull, J., Ghanny, S., et al. Endometrial carcinoma biomarker discovery and verification using differentially tagged clinical samples with multidimensional liquid chromatografy and tandem mass spectrometry. Molecular&Cellular Proteomics, 2007, 6, p. 1170-1182.

8. Fogel, M., Huszar, M., Altevogt, P., Ben, AA. L1 (CD 171) as a novel biomarker for ovarian and endometrial carcinomas. Expert Rev Mol Diagn, 2004, 4, p. 455- 462.

9. Howard, BA., Furumain, R., Campa, MJ., et al. Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. Cancer Res, 2005, 65, p. 8853-8860.

10. Huang, CM., Ananthaswamy, HN., Barnes, S., et al. Mass spectrometric proteomics profiles of in vivo tumor secretomes: capillary ultrafiltration sampling of regressive tumor masses. Proteomics, 2006, 6, p. 6107-6116.

11. Chen, J., He, QY., Yuen, AP., Chiu, JF. Proteomics of buccal squamous cell carcinoma: the involvement of multiple pathways in tumorogenesis. Proteomics, 2004, 4, p. 2465-2475.

12. Ioachin, E. Immunohistochemical tumour markers in endometrial carcinoma. Eur J Gynaecol Oncol, 2005, 26, p. 363-371.

13. Jin, ZG., Melaragno, MG., Liao, DF., et al. Cyclophilin A is a secreted growth factor induced by oxidative stress. Circ Res, 87, p. 789-796.

14. Kacerovský, M., Tošner, J., Lenčo, J., Tambor, V. Proteomika a karcinom ovaria. Čes Gynek, 2009, 74, s. 163-170.

15. Konstantakopoulos, N., Montgomery, KG., Chamberlein, N., et al. Changes in gene expressions elicited by physiological concentrations of genistein on human endometrial cancer. Mol Carcinog, 2006, 45, p. 752-763.

16. Lecocq, R., Lamy, R., Erneux, C., Dumont, JE. Rapid purification and identification of calcyphosine, a CA2+ - binding protein phoshorylated by protein kinase A. Biochem J, 1995, 306, p. 147-151.

17. Li, Z., Zhao, X., Bai, S., et al. Proteomics identification of cyclophilin A as a potential prognostic factor and therapeutic target in endometrial carcinoma. Molecular & Cellular Proteomics, 2008, 7, p. 1810-1823.

18. Lim, SO., Park, SJ., Kim, W., et al. Proteome analysis of hepatocellular carcinoma. Biochem Biophys Res Commun, 2002, 291, p. 1031-1037.

19. Mazurek, S., Boschek, CB., Hugo, F., Eigenbrodt, E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol, 2005, 15, p. 300-308.

20. Mermarzadeh, S., Kozak, KR., Chang, L., et al. Urokinase plasminogen activator receptor: prognostic biomarker for endometrial cancer. Proc Natl Acad Sci USA 2002, 99, p. 10647-10652.

21. Meza-Zepeda, LA. Forus, A., Lygren, B., et al. Positional cloning identifies a novel cyclophylin as a candindate amplified oncogene in 1q21. Oncogene, 2002, 21, p. 2261-2269.

22. Okada, H., Nakajima, T, Yoshimura, T., et al. Microarray analysis of genes controled by progesterone in human endometrial stromal cells in vitro. Gynecol Endocrinol, 2003, 17, p. 271-280.

23. Pappa, KI, Choleza, M, Markari, S., et al. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS station status. Gynecol Oncol, 2006, 100, p. 596-600.

24. Parkin, DM., Pisani, P, Ferlay, J. Global cancer statistics. CA Cancer J Clin, 1999, 49, p. 33-64.

25. Petricoin, EF., Zoon, KC. Kohn, EC. Barrett, JC. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discover, 2002, 1, p. 683-695.

26. Ragni, N., Ferrero, S., Prefumo, F., et al. The association between p53 expression, stage and histological features in endometrial cancer. Eur J Obstet Gynecol Reprod Bio, 2005, 123, p. 111-116.

27. Shen, J., Person, MD., Zhu, J., et al. Protein expression profiles in panceratic adenocarcinoma compared with normal panceratic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res, 2004, 64, p. 9018-9026.

28. Shibata, K., Kikkawa, F., Kondo, C., et al. Placental leucine aminopeptidase expression is associated with chemosenzitivity in human endometrial carcinona. Gynecol Oncol, 2004, 95, p. 307-313.

29. Shih, MC., Yek, KT., Tang, KP., Chen, JC. Promoter methylation in circadian genes of endometrial cancers detected by methylation-specific PCR. Mol Carcinog, 2006, 45, p. 732-740.

30. Shiozawa, T., Konishi, I. Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis and treatment. Int J Clin Oncol, 2006, 11, p. 13-21.

31. Schjerven, H., Brandtzaeg, P., Johansen, FE. Mechanism of IL-4 mediated up-regulation of the polymeric Ig receptor: role of STAT6 in cell type specific delayed transcriptional response. J Immunol, 2000, 165, p. 3898-3906.

32. Schneider, J., Bitterlich, N., Schultze, G. Improved senzitivity in the diagnostic of gastrointestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK. Anticancer res. 2005, 25, p. 1507-1515.

33. Tu, Z., Gui, L., Wang, J., et al. Tumorigenesis of K-ras station in human endometrial carcinoma via upregulation of estrogen receptor. Gynecol Oncol, 2006, 101, p. 274-279.

34. Uegaki, I., Kanamori, Y., Kigawa, J., et al. PTEN positive and phosphorylated – Akt- negative expression is a predictor of survival for patients with advanced endometrial cancer. Oncol Rep, 2005, 14, p. 389-392.

35. Ugurel, S., Bell, N., Sucker, A., et al. Tumor type M2 pyruvate kinase (TUM2-PK) as a novel plasma tumor marker in melanoma. Int J Cancer, 2005, 117, p. 825-830.

36. Yang, EC., Guo, J., Diehl, G., et al. Protein expression profilig of endometrial malignancies revers a new tumor marker:chaperonin 10. J Proteome Res. 2004, 3, p. 636-643.

37. Young, CL., Feierstein, A., Southwick, FS. Calcium regulation of actin filament capping and monomer binding by macrophage capping protein. J Biol Chem, 1994, 269, p. 11997-14002.

38. Yu, CJ., Yang, PC., Shun, CT., et al. Overexpression of MUC5 genes is associated with early postoperative metastasis in non-small cell lung cancer. Int J Cancer, 1996, 69, p. 457-465.

39. Zierau, O., O’Sullivan, J., Morrisey, C., et al. Tamoxifen exerts agonistic effects on clusterin and complement C3 gene expression in RUCA-I primary xenografts and metastases but normal uterus. Endocr Relat Cancer, 2004, 11, p. 823-830.